The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Here's what doctors want you to know about Spravato, plus potential side effects to be aware of. Thea Gallagher, PsyD, is a clinical associate professor at NYU Langone Health and cohost of the ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...

These side effects and the potential risk of harmful dependence have led to the FDA mandating a special treatment strategy for providing Spravato to patients, known as a Risk Evaluation and ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

Spravato’s warning label cautions about the risk of sedation and dissociation, respiratory depression, suicidal thoughts, and abuse or misuse of the drug, among other potential side effects.

Spravato is taken by the user under the supervision of a healthcare provider in a clinic. Because reported side-effects include temporary nausea, vomiting, and tiredness, healthcare supervisors ...